计算溶液所需的质量、体积或浓度。
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Reboxetine mesylate是一种降低肾上腺素重新吸收的抑制剂，抑制[3H]小鼠下丘脑突触体对碘化钾的吸收量和[3H]5-HT小鼠纹状体突触对碘化钾吸收的Ki值分别为8.2nM和1070nM。A selective SLC6A2 inhibitor.
Information
Reboxetine (PNU 155950E) is anorepinephrinereuptake inhibitor withKiof 8.2 nM.
In vitro
Reboxetine dose-dependently and completely inhibits [3H]-dopamine uptake to the human norepinephrine transporters (hNET) with Ki value of 11 nM in Madin–Darby canine kidney (MDCK) cells.
In vivo
Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively. Reboxetine results in a significant reduction in the mean number of panic attacks and phobic symptoms in patients with DSM-III-R panic disorder. Reboxetine also results in improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex. Reboxetine dose dependently decreases nicotine self-administration by ~60%. Repeated administration of Reboxetine (5.6 mg/kg) decreases nicotine self-administration and sucrose-maintained responding across the 14 sessions.
Cell Data
cell lines：HDMECs
Concentrations：
Incubation Time：
Powder Purity:≥99%
规格
别名
甲磺酸瑞波西汀
英文别名
PNU 155950E, FCE20124 mesylate | Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (1:1)
规格或纯度
10mM in DMSO
英文名称
Reboxetine mesylate
生化机理
瑞波西汀（PNU 155950E）是一种去甲肾上腺素再摄取抑制剂，其Ki值为 8.2 nM。
储存条件
-80℃储存
运输条件
特低温运输
名称和识别符
EC号
638-822-2
分子类型
小分子
Isomeric SMILES
CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O
PubChem CID
分子量
409.5
技术文档
高级数据
安全和危险性（GHS）
信号词
危险
危险声明
H302: 吞食有害
H360: 可能损害生育力或未出生的孩子
H373: 通过长时间或反复暴露对器官造成损害
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）